Legend Biotech ADRs Climb on Preliminary Study Results for Non-Hodgkin Lymphoma Treatment

Dow Jones06-03 01:58

By Kelly Cloonan

American depositary receipts of Legend Biotech gained after the company said it observed promising early clinical evidence for a therapy aimed at treating non-Hodgkin lymphoma.

ADRs climbed 40% to $35.60 on Tuesday, and are now up 64% year to date.

In an ongoing Phase 1 study of 12 patients with relapsed or refractory B-cell non-Hodgkin lymphoma, Legend Biotech's CAR-T cell therapy LB2501 demonstrated a 100% objective response rate and an 83% complete response rate.

The company said the data supports the potential of an in vivo CAR-T approach in B-cell malignancies. LB2501 is designed to generate CAR-T cells directly within a patient following an intravenous infusion, eliminating the need for cell manufacturing and lymphodepletion, the company said.

"By generating CAR-T cells directly within the patient, this approach has the potential to simplify treatment delivery and expand access for patients who may not be able to receive traditional CAR-T cell therapies," Chief Executive Ying Huang said.

Non-Hodgkin lymphoma is one of the most common types of cancers in the U.S. The American Cancer Society estimates about 79,320 people will be diagnosed with non-Hodgkin lymphoma in 2026, and about 19,970 people will die from it.

B-cell lymphomas account for about 85% of NHL cases, Legend Biotech said.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

June 02, 2026 13:58 ET (17:58 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2640470549?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 01:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640470549","market":"sh","top_or_hot":-1,"title":"Legend Biotech ADRs Climb on Preliminary Study Results for Non-Hodgkin Lymphoma Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  American depositary receipts of Legend Biotech gained after the company said it observed promising early clinical evidence for a therapy aimed at treating non-Hodgkin lymphoma. \n</p>\n<p>\n  ADRs climbed 40% to $35.60 on Tuesday, and are now up 64% year to date. \n</p>\n<p>\n  In an ongoing Phase 1 study of 12 patients with relapsed or refractory B-cell non-Hodgkin lymphoma, Legend Biotech's CAR-T cell therapy LB2501 demonstrated a 100% objective response rate and an 83% complete response rate. \n</p>\n<p>\n  The company said the data supports the potential of an in vivo CAR-T approach in B-cell malignancies. LB2501 is designed to generate CAR-T cells directly within a patient following an intravenous infusion, eliminating the need for cell manufacturing and lymphodepletion, the company said. \n</p>\n<p>\n  \"By generating CAR-T cells directly within the patient, this approach has the potential to simplify treatment delivery and expand access for patients who may not be able to receive traditional CAR-T cell therapies,\" Chief Executive Ying Huang said. \n</p>\n<p>\n  Non-Hodgkin lymphoma is one of the most common types of cancers in the U.S. The American Cancer Society estimates about 79,320 people will be diagnosed with non-Hodgkin lymphoma in 2026, and about 19,970 people will die from it. \n</p>\n<p>\n  B-cell lymphomas account for about 85% of NHL cases, Legend Biotech said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 02, 2026 13:58 ET (17:58 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Legend Biotech ADRs Climb on Preliminary Study Results for Non-Hodgkin Lymphoma Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLegend Biotech ADRs Climb on Preliminary Study Results for Non-Hodgkin Lymphoma Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-03 01:58</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  American depositary receipts of Legend Biotech gained after the company said it observed promising early clinical evidence for a therapy aimed at treating non-Hodgkin lymphoma. \n</p>\n<p>\n  ADRs climbed 40% to $35.60 on Tuesday, and are now up 64% year to date. \n</p>\n<p>\n  In an ongoing Phase 1 study of 12 patients with relapsed or refractory B-cell non-Hodgkin lymphoma, Legend Biotech's CAR-T cell therapy LB2501 demonstrated a 100% objective response rate and an 83% complete response rate. \n</p>\n<p>\n  The company said the data supports the potential of an in vivo CAR-T approach in B-cell malignancies. LB2501 is designed to generate CAR-T cells directly within a patient following an intravenous infusion, eliminating the need for cell manufacturing and lymphodepletion, the company said. \n</p>\n<p>\n  \"By generating CAR-T cells directly within the patient, this approach has the potential to simplify treatment delivery and expand access for patients who may not be able to receive traditional CAR-T cell therapies,\" Chief Executive Ying Huang said. \n</p>\n<p>\n  Non-Hodgkin lymphoma is one of the most common types of cancers in the U.S. The American Cancer Society estimates about 79,320 people will be diagnosed with non-Hodgkin lymphoma in 2026, and about 19,970 people will die from it. \n</p>\n<p>\n  B-cell lymphomas account for about 85% of NHL cases, Legend Biotech said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 02, 2026 13:58 ET (17:58 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2640470549","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640470549","pubTimestamp":1780423080,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"American depositary receipts of Legend Biotech gained after the company said it observed promising early clinical evidence for a therapy aimed at treating non-Hodgkin lymphoma.ADRs climbed 40% to $35.60 on Tuesday, and are now up 64% year to date.In an ongoing Phase 1 study of 12 patients with relapsed or refractory B-cell non-Hodgkin lymphoma, Legend Biotech's CAR-T cell therapy LB2501 demonstrated a 100% objective response rate and an 83% complete response rate.The company said the data supports the potential of an in vivo CAR-T approach in B-cell malignancies. LB2501 is designed to generate CAR-T cells directly within a patient following an intravenous infusion, eliminating the need for cell manufacturing and lymphodepletion, the company said.\"By generating CAR-T cells directly within the patient, this approach has the potential to simplify treatment delivery and expand access for patients who may not be able to receive traditional CAR-T cell therapies,\" Chief Executive Ying Huang s","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4581":"高盛持仓","CAR":"安飞士","XBI":"SPDR S&P Biotech ETF","BK4022":"陆运","BK4230":"旅客陆运","BK4588":"碎股","LEGN":"传奇生物","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓"},"translate_title":"传奇生物ADR因非霍奇金淋巴瘤治疗初步研究结果而攀升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XBI":1.5,"CAR":0.73,"LEGN":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  American depositary receipts of Legend Biotech gained after the company said it observed promising early clinical evidence for a therapy aimed at treating non-Hodgkin lymphoma. \n\n\n  ADRs climbed 40% to $35.60 on Tuesday, and are now up 64% year to date. \n\n\n  In an ongoing Phase 1 study of 12 patients with relapsed or refractory B-cell non-Hodgkin lymphoma, Legend Biotech's CAR-T cell therapy LB2501 demonstrated a 100% objective response rate and an 83% complete response rate. \n\n\n  The company said the data supports the potential of an in vivo CAR-T approach in B-cell malignancies. LB2501 is designed to generate CAR-T cells directly within a patient following an intravenous infusion, eliminating the need for cell manufacturing and lymphodepletion, the company said. \n\n\n  \"By generating CAR-T cells directly within the patient, this approach has the potential to simplify treatment delivery and expand access for patients who may not be able to receive traditional CAR-T cell therapies,\" Chief Executive Ying Huang said. \n\n\n  Non-Hodgkin lymphoma is one of the most common types of cancers in the U.S. The American Cancer Society estimates about 79,320 people will be diagnosed with non-Hodgkin lymphoma in 2026, and about 19,970 people will die from it. \n\n\n  B-cell lymphomas account for about 85% of NHL cases, Legend Biotech said. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 02, 2026 13:58 ET (17:58 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640470549","isCrawlerRequest":true}